Galapagos Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 6/6

Galapagos hat ein Gesamteigenkapital von €2.9B und eine Gesamtverschuldung von €0.0, was einen Verschuldungsgrad von 0% ergibt. Die Gesamtaktiva und Gesamtpassiva betragen €4.2B bzw. €1.3B.

Wichtige Informationen

Verhältnis von Schulden zu Eigenkapital

€0

Verschuldung

Zinsdeckungsgrad	n/a
Bargeld	€3.34b
Eigenkapital	€2.86b
Gesamtverbindlichkeiten	€1.31b
Gesamtvermögen	€4.17b

Jüngste Berichte zur Finanzlage

Here's Why We're Not Too Worried About Galapagos' (AMS:GLPG) Cash Burn Situation

Mar 29

Recent updates

€41.78: That's What Analysts Think Galapagos NV (AMS:GLPG) Is Worth After Its Latest Results

May 06

Here's Why We're Not Too Worried About Galapagos' (AMS:GLPG) Cash Burn Situation

Mar 29

Analyse der Finanzlage

Kurzfristige Verbindlichkeiten: GLPGDie kurzfristigen Aktiva des Unternehmens (€3.6B) übersteigen seine kurzfristigen Passiva (€351.2M).

Langfristige Verbindlichkeiten: GLPGDie kurzfristigen Vermögenswerte des Unternehmens (€3.6B) übersteigen seine langfristigen Verbindlichkeiten (€958.4M).

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Verschuldungsgrad: GLPG ist schuldenfrei.

Schulden abbauen: GLPG hatte vor 5 Jahren keine Schulden.

Bilanz

Liquiditätsreserve-Analyse

Bei Unternehmen, die in der Vergangenheit im Durchschnitt Verluste gemacht haben, wird geprüft, ob sie über einen Liquiditätsvorlauf von mindestens einem Jahr verfügen.

Stabile Start- und Landebahn für Bargeld: GLPG auf der Grundlage seines derzeitigen freier Cashflows über eine ausreichende Liquiditätsreserve für mehr als 3 Jahre verfügt.

Vorhersage Cash Runway: GLPG über eine ausreichende Liquiditätsreserve für mehr als 3 Jahre verfügt, wenn der freie Cashflow weiterhin mit historischen Raten von 37.4% pro Jahr zurückgeht

Galapagos Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 6/6

Wichtige Informationen

Jüngste Berichte zur Finanzlage

Here's Why We're Not Too Worried About Galapagos' (AMS:GLPG) Cash Burn Situation

Recent updates

Consensus EPS estimates fall from profit to €1.27 loss

Forecast to breakeven in 2024

New minor risk - Profitability

Galapagos NV to Report First Half, 2025 Results on Jul 23, 2025

Consensus EPS estimates increase by 185%

Consensus EPS estimates fall by 23%

Galapagos NV Announces Board Changes

Consensus EPS estimates fall by 49%

Investor sentiment improves as stock rises 17%

Galapagos Announces FDA Clearance of IND Application for Phase 1/2 ATALANTA-1 study of CD19 CAR-T, GLPG5101, in Relapsed/Refractory Non-Hodgkin Lymphoma

Second quarter 2024 earnings released

Galapagos NV to Report Fiscal Year 2024 Results on Feb 12, 2025

Consensus EPS estimates fall by 10%

Consensus EPS estimates upgraded to €0.72 loss, revenue downgraded

First quarter 2024 earnings released: EPS: €0.36 (vs €0.35 in 1Q 2023)

Galapagos NV (AMS:GLPG) Analysts Are More Bearish Than They Used To Be

Consensus revenue estimates decrease by 11%

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Galapagos NV Announces Board Changes

New major risk - Revenue and earnings growth

Galapagos NV to Present New Preliminary Translational Data at EBMT-EHA Annual Meeting 2024

Alfasigma S.p.A. completed the acquisition of Filgotinib business from Galapagos NV (ENXTAM:GLPG).

Consensus EPS estimates fall by 14%

Galapagos NV's (AMS:GLPG) Shares Lagging The Industry But So Is The Business

Michele Manto to Join Alfasigma and Resigns from His Position as Chief Commercial Officer and Executive Committee Member At Galapagos

Galapagos Announces Start of PAPILIO-1 Phase 1/2 Multiple Myeloma Study of Point-Of-Care Manufactured BCMA CAR-T Candidate, GLPG5301

Galapagos Presents New Encouraging Clinical Data from the Ongoing Phase 1/2 CD19 CAR-T Studies with GLPG5201 and GLPG5101

Consensus estimates of losses per share improve by 31%

Consensus estimates of losses per share improve by 13%

Consensus EPS estimates fall by 27%

Galapagos NV to Report First Half, 2024 Results on Aug 01, 2024

Third quarter 2023 earnings released: EPS: €0.39 (vs €0.33 in 3Q 2022)

High number of new directors

Galapagos NV Announces Board Changes

Galapagos NV to Report Q4, 2023 Results on Mar 28, 2024

Galapagos NV Announces Start of Phase 2 Study with Selective Tyk2 Inhibitor, GLPG3667, in Patients with Active Systemic Lupus Erythematosus

Consensus estimates of losses per share improve by 12%

New major risk - Revenue and earnings growth

Galapagos NV Revises Sales Guidance for the Full Year 2023

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Lacklustre Performance Is Driving Galapagos NV's (AMS:GLPG) Low P/S

Galapagos Appoints Thad Huston as Chief Financial Officer, Effective from July 1, 2023

Galapagos NV Announces Director Changes

Galapagos to Showcase CAR-T Point-Of-Care Manufacturing and Initial Phase 1/2 CLL Data with CD19 CAR-T Candidate, GLPG5201, at the EHA 2023 Congress

Consensus EPS estimates fall by 30%

Consensus EPS estimates fall by 19%

Consensus EPS estimates upgraded to €2.71 loss, revenue downgraded

€41.78: That's What Analysts Think Galapagos NV (AMS:GLPG) Is Worth After Its Latest Results

First quarter 2023 earnings released: EPS: €0.35 (vs €0.20 loss in 1Q 2022)

Price target decreased by 8.1% to €41.78

Here's Why We're Not Too Worried About Galapagos' (AMS:GLPG) Cash Burn Situation

Full year 2022 earnings: EPS and revenues miss analyst expectations

Consensus EPS estimates upgraded to €1.17 loss, revenue downgraded

Full year 2022 earnings released: €3.32 loss per share (vs €1.92 loss in FY 2021)

Price target decreased by 13% to €47.62

Galapagos NV Announces Topline Results from Phase 3 DIVERSITY Trial of Filgotinib in Crohn’s Disease

Consensus EPS estimates fall by 48%

Galapagos NV Announces Changes in the Executive Committee Effective 1 January 2023

Galapagos and CellPoint Presented Encouraging Initial Data AtASH 2022 for GLPG5101, a CD19 CAR-T Candidate Manufactured At Point-Of-Care

Consensus forecasts updated

Price target decreased to €52.86

Consensus estimates of losses per share improve by 84%

Galapagos Announces CHMP Adoption of PRAC’s Recommendation for Jyseleca® Following Extensive Safety Review of all JAK Inhibitors

Galapagos NV to present encouraging initial data from FILOSOPHY real-world arthritis study at ACR Convergence 2022

Galapagos NV to Report Fiscal Year 2022 Final Results on Mar 23, 2023

Third quarter 2022 earnings released: EPS: €0.30 (vs €0.99 loss in 3Q 2021)

Galapagos NV to Report Q1, 2023 Results on May 04, 2023

Galapagos Receives Positive CHMP Opinion for Jyseleca® European Label Update Based on Testicular Function Safety Data from MANTA/RAy Studies

Galapagos NV announced that it has received €3.07625 million in funding

Consensus EPS estimates have been downgraded.

Consensus forecasts updated

Galapagos NV Revises Revenue Guidance of Jyseleca for the Full Year 2022

Second quarter 2022 earnings released: €0.29 loss per share (vs €0.98 loss in 2Q 2021)

Consensus forecasts updated